Clinical trials: Psychological Disorders
Huntington's Disease
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.
- Trial name
- SIGNAL-HD (NCT02481674)
- Testing
- VX15/2503
- Where
- 32 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Vaccinex Inc.
Depression
Nexalin Therapy for the Treatment of Depressive Symptoms
The primary objectives of this Phase II study are to demonstrate the safety of Nexalin Therapy and to investigate the efficacy of Nexalin Therapy.
- Trial name
- NCT00774813
- Testing
- Nexalin 1.3mA Device, Nexalin 15mA device
- Where
- 2 sites in Russia
- Volunteers
- 120 people
- Sponsor
- Kalaco Scientific, Inc.
Schizophrenia
Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics
The purpose of this non-interventional, observational and international registry study is to document the prescribing patterns in daily clinical practice and to assess long term treatment outcomes related to initiation of…
- Trial name
- PILAR (NCT00696813)
- Where
- 84 sites in Canada, Czechia and 5 more
- Volunteers
- 3,064 people
- Sponsor
- Janssen-Cilag International NV
Depressive Disorder, Major
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).
- Trial name
- NCT00413023
- Testing
- GW679769
- Where
- 39 sites in Argentina, Belgium and 9 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder
- Trial name
- NCT01034462
- Testing
- Levomilnacipran ER
- Where
- 23 sites in United States
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Schizophrenia
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00615433
- Testing
- Lurasidone, Olanzapine, Lurasidone 40 mg tablets
- Where
- 52 sites in United States, Colombia and 3 more
- Volunteers
- 478 people
- Sponsor
- Sumitomo Pharma America, Inc.
Anxiety
CHI-907 CBD Extract and Experiences of Test Anxiety
This is a randomized, placebo-controlled study examining the effects of CHI-907 on test anxiety specifically, and state anxiety more broadly.
- Trial name
- NCT04269252
- Testing
- CHI-907, CHI-804
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
Schizophrenia
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone, In Schizophrenic Patients Previously…
- Trial name
- NCT00722176
- Testing
- BL-1020, BL-1020 10-30 mg, risperidone
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- BioLineRx, Ltd.
Psychosocial Deprivation, Work-Related Stress
Family Supportive Supervisor Training and Workplace Assessment Tool
This study will evaluate the effectiveness of FSST 2.0 (family supportive supervisor training plus support for use of family and sick leaves) using a randomized control trial design.
- Conditions
- Psychosocial Deprivation, Work-Related Stress, Life-work Imbalance
- Trial name
- FSST (NCT05080426)
- Testing
- Family Supportive Supervisor Training 2.0
- Where
- United States
- Volunteers
- 1,175 people, healthy volunteers welcome
- Sponsor
- Work Life Help
Major Depressive Disorder (MDD)
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics…
- Trial name
- NCT00330616
- Testing
- 323U66 SR
- Where
- 9 sites in Japan
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Huntington's Disease
Efficacy and Safety of Tetrabenazine in Chorea
The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
- Trial name
- NCT00219804
- Sponsor
- Prestwick Pharmaceuticals
Mild Cognitive Impairment
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
- Trial name
- NCT06347315
- Testing
- BrainXpert
- Where
- 28 sites in France, Germany and 4 more
- Volunteers
- 380 people
- Sponsor
- Société des Produits Nestlé (SPN)
Major Depressive Disorder
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation…
- Trial name
- NCT00063206
- Testing
- DVS-233 SR
- Volunteers
- 247 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Attention Deficit Disorder With Hyperactivity
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether a controlled release formulation of mazindol is more effective than a placebo in the treatment of Attention Hyperactivity Disorder (ADHD) in adults.
- Trial name
- NCT02808104
- Testing
- mazindol
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- NLS Pharmaceutics
Schizophrenia
An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone
The purpose of this study is to assess treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
- Trial name
- e-STAR (NCT00774085)
- Testing
- No intervention was given
- Volunteers
- 408 people
- Sponsor
- Janssen Cilag N.V./S.A.
Erectile Dysfunction
Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)
This study is designed to evaluate the efficacy and safety of MED2005, a topically applied glyceryl trinitrate (GTN) gel administered to the penis of male subjects self-diagnosed with erectile dysfunction (ED) immediately before…
- Trial name
- NCT02495467
- Testing
- Glyceryl trinitrate
- Where
- United Kingdom
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Futura Medical Developments Ltd.
Alzheimer Disease
Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia
This randomized, sham-controlled, exploratory clinical trial will evaluate the efficacy and safety of HeLaXON, an investigational low-dose radiation therapy device, in patients with mild Alzheimer's disease dementia.
- Trial name
- LDRT-AD-03 (NCT07863011)
- Testing
- HeLaXON 1X Low-Dose Radiation Therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- ReadyCure Inc.
Major Depressive Disorder
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response…
- Trial name
- NCT06633016
- Testing
- ABX-002
- Where
- 50 sites in United States
- Volunteers
- 230 people
- Sponsor
- Autobahn Therapeutics, Inc.
Major Depressive Disorder
Zelquistinel in the Treatment of Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
- Trial name
- AGN-241751 (NCT03726658)
- Testing
- AGN-241751
- Where
- 5 sites in United States
- Volunteers
- 226 people
- Sponsor
- Syndeio Biosciences, Inc
Schizophrenia
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
This is a 12-week study for the treatment of chronic persistent symptoms in participants with schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics who fulfill the screening criteria will be…
- Trial name
- NCT00086593
- Testing
- lamotrigine
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 209 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.